Alle verbonden artikelen

Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.

Auteurs : Pradeep CR, Zeisel A, Köstler WJ, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, Amariglio N, Ben-Chetrit N, Emde A, Solomonov I, Neufeld G, Piccart-Gebhart M, Sagi I, Sotiriou C, Rechavi G, Domany E, Desmedt C, Yarden Y
Jaar : 2012
Journal : Oncogene
Volume : 31(31)
Pagina's : 3569-83

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

Auteurs : Guiu S, Michiels S, André F, Cortes J, Denkert C, Di Leo A, Hennessy BT, Sorlie T, Sotiriou C, Turner N, van de Vijver M, Viale G, Loi S, Reis-Filho JS
Jaar : 2012
Journal : Ann Oncol
Volume : 23
Pagina's : 2997-3006

Neoadjuvant chemotherapy and targeted therapies: a promising strategy.

Auteurs : Metzger-Filho O, de Azambuja E
Jaar : 2011
Journal : J. Natl. Cancer Inst. Monographs
Volume : 2011(43)
Pagina's : 116-9

Strategies for subtypes – dealing with the diversity of breast cancer:Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early breast cancer 2011.(+ Panel Members)

Auteurs : Goldhirsch A, Wood WC, Coates AS, Gelber Rd, Thurliman B, Senn HJ, + collaborators (among others :, Piccart-Gebhart M
Jaar : 2011
Journal : Ann Oncol
Volume : 22(8)
Pagina's : 1736-47

Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?

Auteurs : Klastersky J, Awada A
Jaar : 2011
Journal : Crit Rev Oncol Hematol
Volume : 78(1)
Pagina's : 17-23

International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).

Auteurs : Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, Daidone M, Conte P, Kennedy D, Damia G, Petronini P, Di Cosimo S, Bruzzi P, Dowsett M, Desmedt C, Mansel RE, Olivetti L, Tondini C, Sapino A, Fenaroli P, Tortora G, Thorne H, Bertolini F, Ferrozzi F, Danova M, Tagliabue E, de Azambuja E, Makris A, Tampellini M, Dontu G
Jaar : 2011
Journal : J. Natl. Cancer Inst. Monographs
Volume : 2011(43)
Pagina's : 147-51

Prevention of neutropenia-related events in elderly patients with haematological cancer

Auteurs : Klastersky J, Gombos A, Georgala A, Awada A
Jaar : 2011
Journal : Aging Health
Volume : 7(6)
Pagina's : 829-42

Febrile neutropenia: a critical review of the initial management.

Auteurs : Klastersky J, Awada A, Paesmans M, Aoun M
Jaar : 2011
Journal : Crit Rev Oncol Hematol
Volume : 78(3)
Pagina's : 185-94

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.

Auteurs : Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, Avkiran M, de Azambuja E, Balligand JL, Brutsaert DL, Condorelli G, Hansen A, Heymans S, Hill JA, Hirsch E, Hilfiker-Kleiner D, Janssens S, de Jong S, Neubauer G, Pieske B, Ponikowski P, Pirmohamed M, Rauchhaus M, Sawyer D, Sugden PH, Wojta J, Zannad F, Shah AM
Jaar : 2011
Journal : Eur. J. Heart Fail.
Volume : 13(1)
Pagina's : 1-10

Proteomic changes associated with breast cancer progression in the MCF10AT model.

Auteurs : Fumagalli D, Michiels S, Sotiriou C
Jaar : 2011
Journal : Pharmacogenomics
Volume : 12(1)
Pagina's : 9-10

Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?

Auteurs : Paesmans M, Klastersky J, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Ameye L
Jaar : 2011
Journal : Support Care Cancer
Volume : 19(7)
Pagina's : 1001-8

Motherhood after breast cancer: searching for la dolce vita.

Auteurs : Azim HA, Peccatori FA, de Azambuja E, Piccart-Gebhart M
Jaar : 2011
Journal : Expert Rev Anticancer Ther
Volume : 11(2)
Pagina's : 287-98

A time series evaluation of the in vivo effect of letrozole on gene expression in breast cancer.

Auteurs : Fumagalli D, Michiels S, Sotiriou C
Jaar : 2011
Journal : Pharmacogenomics
Volume : 12(1)
Pagina's : 10

Gene-expression changes over time in a tamoxifen-treated breast cancer xenograft model.

Auteurs : Fumagalli D, Michiels S, Sotiriou C
Jaar : 2011
Journal : Pharmacogenomics
Volume : 12(1)
Pagina's : 11

Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?

Auteurs : Bozovic-Spasojevic I, Azim HA, Paesmans M, Suter T, Piccart-Gebhart M, de Azambuja E
Jaar : 2011
Journal : Lancet Oncol
Volume : 12(3)
Pagina's : 209-11

CD44+ CD24-/low phenotype and resistance to trastuzumab in HER2-positive breast cancer cell lines.

Auteurs : Fumagalli D, Michiels S, Sotiriou C
Jaar : 2011
Journal : Pharmacogenomics
Volume : 12(1)
Pagina's : 12-3

Multifactorial approach to predicting resistance to anthracyclines.

Auteurs : Desmedt C, Di Leo A, de Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J, Delaloge S, Duhem C, Kains JP, Carly B, Maerevoet M, Vindevoghel A, Rouas G, Lallemand F, Durbecq V, Cardoso F, Salgado R, Rovere R, Bontempi G, Michiels S, Buyse M, Nogaret JM, Qi Y, Symmans F, Pusztai L
Jaar : 2011
Journal : J. Clin. Oncol.
Volume : 29(12)
Pagina's : 1578-86

Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis.

Auteurs : Filho OM, Ignatiadis M, Sotiriou C
Jaar : 2011
Journal : Crit Rev Oncol Hematol
Volume : 77(1)
Pagina's : 20-9

Breast cancer: Should we assess HER2 status by Oncotype DX?

Auteurs : Ignatiadis M, Sotiriou C
Jaar : 2011
Journal : Nat Rev Clin Oncol
Volume : 9(1)
Pagina's : 12-4

Long-term toxic effects of adjuvant chemotherapy in breast cancer.

Auteurs : Azim HA, de Azambuja E, Colozza M, Bines J, Piccart-Gebhart M
Jaar : 2011
Journal : Ann Oncol
Volume : 22(9)
Pagina's : 1939-47